

# Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.

NCT07152366

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 4
<b>Sponsor</b>	Shanghai Changzheng Hospital
<b>Enrollment</b>	96 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- Diagnosed with TAO by Bartley criteria.
- Moderate to severe patients defined by EUGOGO.
- CAS e4 (on the 7-item scale) for the study eye.
- participants have received glucocorticoid treatment for TAO in the past but did not responsive or has an unsatisfactory effect.

### Exclusion (12)

- Anticipated need for intervention due to sight-threatening complications or other significant and acute deterioration in vision.
- Combined with other lesions in the orbit.
- Receive orbital radiotherapy or surgical treatment for TED, including orbital decompression, strabismus surgery and eyelid retraction correction.
- During the screening period, if either ear has a history of tinnitus or other hearing impairment; Or abnormal pure tone audiometry results (defined as an average bone conduction hearing threshold of e25 dB at 0.5, 1, 2, 4 kHz or a bone conduction hearing threshold of e40 dB at any frequency).
- At the time of screening, aspartate aminotransferase (AST) or alanine aminotransferase (ALT)  $\gt$  3 times ULN, or accompanied by active hepatitis B (defined as HBsAg positive with HBV-DNA load greater than 1000 IU/mL), or being receiving anti-hepatitis B virus treatment.

... and 7 more (see full listing online)

## Locations (1 total)

---

Shanghai Changzheng Hospital, Shanghai, Shanghai Municipality, China